Skip to content

BONESUPPORT to Showcase CERAMENT® BONE VOID FILLER at Two Upcoming US Orthopedic Conferences

Lund, Sweden, 08:00 CET, 08 October 2018 – BONESUPPORT, an emerging leader in orthobiologics for the management of bone voids, today announces that its US commercial team will be showcasing CERAMENT®|BONE VOID FILLER (CERAMENT®|BVF) at two important US orthopedic conferences taking place in October.

These marketing activities are taking place just ahead of the launch of BONESUPPORT ‘s own US network of independent distributors that will be selling CERAMENT BVF direct beginning 21 October 2018.

The two meetings that BONESUPPORT will attend are:

  • The Musculoskeletal Tumor Society 2018 Annual Meeting, which will take place at the Memorial Sloan Kettering Cancer Center – New York, NY – 10-12 October. The meeting, which will have over 250 attendees, is focused on orthopedic oncology, one of BONESUPPORT’s key target indications.
  • The 34th Annual Meeting of the Orthopedic Trauma Association, which will be held in Kissimmee, Florida, FL – 17-20 October. The OTA meeting program includes presentations on the latest cutting-edge, high quality research and state-of-the-art treatments for musculoskeletal injuries and is expected to draw attendance of 1,600 delegates. Trauma is also a key target indication for BONESUPPORT with CERAMENT BVF


Patrick O’Donnell, General Manager & Executive Vice President of Commercial Operations US, said “We are making excellent progress in building our own US network of high-quality independent distributors that will start selling CERAMENT BVF direct on 21 October. Our attendance at these two important meetings will allow us to further strengthen our relationships with orthopedic surgeons, focused on trauma, hip arthroplasty, foot & ankle, and orthopedic oncology. Given our progress in building our distributor network, I am confident that BONESUPPORT’s US business will deliver significant sales growth in 2019.”


BONESUPPORT is an innovative and rapidly growing commercial stage orthobiologics company, based in Lund, Sweden. The Company develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs directly into the bone void.

BONESUPPORT’s bio-ceramic bone graft substitutes CERAMENT® BONE VOID FILLER (BVF), CERAMENT® G* and CERAMENT® V* are all based on the Company’s novel and proprietary technology platform.

The Company’s products are targeting a large addressable market opportunity across trauma, chronic osteomyelitis (bone infection), revision arthroplasty (replacement of a joint prosthesis), ortho-oncology, foot and ankle, and infected diabetic foot.

BONESUPPORT’s total sales increased from SEK 62 million in 2015 to SEK 129 million in 2017, representing a compound annual growth rate of 45%.

The Company’s research and development is focused on the continuing development and refinement of its CERAMENT technology to extend its use into additional indications by the elution of drugs and therapeutic agents. The Company currently has a pipeline of pre-clinical product candidates that have been designed to promote bone growth.

In addition, BONESUPPORT is looking at opportunities to expand its product offering in the US and has entered into a strategic agreement with MTF Biologics and Collagen Matrix Inc. to market and distribute products that are complementary to CERAMENT BVF.

BONESUPPORT is listed on Nasdaq Stockholm and trades under the ticker “BONEX” (ISIN code: SE0009858152). Further information is available at

*CERAMENT G: Not available in the United States, for investigational use only.
CERAMENT V: Not available in the United States.

BONESUPPORT and CERAMENT® are registered trademarks.

For more information contact:



Emil Billbäck, CEO

+46 (0) 46 286 53 70

Björn Westberg, CFO

+46 (0) 46 286 53 60

Citigate Dewe Rogerson

Pip Batty, David Dible, Shabnam Bashir

+44 (0)20 7282 1022

This information is such information as BONESUPPORT HOLDING AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CET on 08 October 2018.

Source: Bonesupport